# A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

> **NCT02373202** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 91 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Sarilumab
- **DRUG:** Sulfasalazine
- **DRUG:** Leflunomide
- **DRUG:** Bucillamine
- **DRUG:** Tacrolimus
- **DRUG:** Mizoribine

## Key facts

- **NCT ID:** NCT02373202
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2018-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02373202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02373202, "A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02373202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*